000277915 001__ 277915
000277915 005__ 20240229155028.0
000277915 0247_ $$2doi$$a10.1007/s10654-023-01031-2
000277915 0247_ $$2pmid$$apmid:37530938
000277915 0247_ $$2ISSN$$a0393-2990
000277915 0247_ $$2ISSN$$a1573-7284
000277915 0247_ $$2altmetric$$aaltmetric:152259796
000277915 037__ $$aDKFZ-2023-01574
000277915 041__ $$aEnglish
000277915 082__ $$a610
000277915 1001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b0$$eFirst author$$udkfz
000277915 245__ $$aWhen gold standards are not so golden: prevalence bias in randomized trials on endoscopic colorectal cancer screening.
000277915 260__ $$aDordrecht [u.a.]$$bSpringer Science + Business Media B.V.$$c2023
000277915 3367_ $$2DRIVER$$aarticle
000277915 3367_ $$2DataCite$$aOutput Types/Journal article
000277915 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1694782202_28749
000277915 3367_ $$2BibTeX$$aARTICLE
000277915 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000277915 3367_ $$00$$2EndNote$$aJournal Article
000277915 500__ $$a#EA:C070#EA:C120#LA:C070# / 2023 Sep;38(9):933-937
000277915 520__ $$aRandomized trials on the effectiveness of screening endoscopy in reducing colorectal cancer (CRC) risk have reported statistically significant, but rather modest reduction of CRC risk by the screening offer. However, risk estimates in these trials included substantial proportions of prevalent CRC cases which were early detected, but could not possibly have been prevented by screening. Thereby, a key principle of randomized prevention trials is violated that only 'at risk' persons who do not yet have the disease one aims to prevent should be included in measures of preventive effects. Using recently published data from the Nordic-European Initiative on Colorectal Cancer (NordICC) trial as an example, we illustrate that approaches aimed to account for 'prevalence bias' lead to effect estimates that are substantially larger than those reported in the trial and more in line with results from observational studies and real life settings. More rigorous methodological work is needed to develop effective and user-friendly tools to prevent or adjust for prevalence bias in future screening studies.
000277915 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000277915 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000277915 650_7 $$2Other$$aBias
000277915 650_7 $$2Other$$aColorectal cancer
000277915 650_7 $$2Other$$aEndoscopy
000277915 650_7 $$2Other$$aIncidence
000277915 650_7 $$2Other$$aPrevalence
000277915 650_7 $$2Other$$aTrial
000277915 7001_ $$00000-0002-1348-3350$$aHeisser, Thomas$$b1
000277915 7001_ $$00000-0002-9155-7415$$aCardoso, Rafael$$b2
000277915 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b3$$eLast author$$udkfz
000277915 773__ $$0PERI:(DE-600)2004992-4$$a10.1007/s10654-023-01031-2$$n9$$p933-937$$tEuropean journal of epidemiology$$v38$$x0393-2990$$y2023
000277915 909CO $$ooai:inrepo02.dkfz.de:277915$$pVDB
000277915 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000277915 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-1348-3350$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000277915 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-9155-7415$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000277915 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000277915 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000277915 9141_ $$y2023
000277915 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2022-11-17$$wger
000277915 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2022-11-17$$wger
000277915 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-17
000277915 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-17
000277915 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-17
000277915 915__ $$0StatID:(DE-HGF)0430$$2StatID$$aNational-Konsortium$$d2023-08-25$$wger
000277915 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J EPIDEMIOL : 2022$$d2023-08-25
000277915 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000277915 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000277915 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000277915 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-25
000277915 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000277915 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-25
000277915 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-25
000277915 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bEUR J EPIDEMIOL : 2022$$d2023-08-25
000277915 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000277915 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000277915 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000277915 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000277915 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000277915 9200_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000277915 980__ $$ajournal
000277915 980__ $$aVDB
000277915 980__ $$aI:(DE-He78)C070-20160331
000277915 980__ $$aI:(DE-He78)C120-20160331
000277915 980__ $$aI:(DE-He78)HD01-20160331
000277915 980__ $$aUNRESTRICTED